Clinical Trial Detail

NCT ID NCT01746251
Title Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Massachusetts General Hospital
Indications

lung non-small cell carcinoma

Therapies

Afatinib

Age Groups: adult

No variant requirements are available.